Assessment of Treatment of Community Acquired Severe Pneumonia by Two Different AntibioticsCorrespondence Address :
Dr. Karimeldin MA Salih,
King Khalid University, College of Medicine, PO box 641, Abha-61421, Kingdom of Saudi Arabia.
E-mail : firstname.lastname@example.org
Introduction: Pneumonia is common presentation in the emergency room and is still a cause of morbidity and mortality. The rationale of this study was to test the trend of paediatricians to achieve rapid response facing severe pneumonia, the lack of agreed on plan for the management of community acquired pneumonia (CAP) and the few experiences regarding injectable form of ß-lactam antimicrobial.
Materials and Methods: This is a prospective case control study, purposive randomized sampling, three patients were excluded since their information was incomplete, 132 patients were randomly divided into groups, one group named control group (penicillin according to the guidelines of WHO 2013), 33 patients; second group treated by ß-lactam inhibitors (Augmentin IV) 50 patients; and third group treated by 3rd generation cephalosporin (ceftriaxone) 49 patients. The study was conducted at the main tertiary care and paediatrics teaching hospital in Khartoum capital of Sudan. The study was completed within the duration from 2010 to 2011.
Results: Both group showed more or less similar results regarding response, as well as the failure rate however, the Augmentin and ceftriaxone groups showed a little bit better survival than the control group.
Conclusion: Antibiotics decrease the mortality rate among the pneumonia patients provided that it is given early in the disease.
Augmentin, Ceftriaxone, Community acquired pneumonia, Empirical treatment
Karimeldin MA Salih, Jalal Ali Bilal, Widad Eldouch, Ali Abdin. ASSESSMENT OF TREATMENT OF COMMUNITY ACQUIRED SEVERE PNEUMONIA BY TWO DIFFERENT ANTIBIOTICS. Journal of Clinical and Diagnostic Research [serial online] 2016 May [cited: 2018 Sep 21 ]; 10:SC06-SC09. Available from
Date of Submission: Dec 25, 2014
Date of Peer Review: Feb 21, 2015
Date of Acceptance: Jul 27, 2015
Date of Publishing: May 01, 2016
Financial OR OTHER COMPETING INTERESTS: None.
- Emerging Sources Citation Index (Web of Science, thomsonreuters)
- Index Copernicus ICV 2016: 132.37
- Academic Search Complete Database
- Directory of Open Access Journals (DOAJ)
- Embase & EMbiology
- Google Scholar
- HINARI Access to Research in Health Programme
- Indian Science Abstracts (ISA)
- Journal seek Database
- Popline (reproductive health literature)